Search results
Showing 1 to 2 of 2 results for ta604
Idelalisib for treating refractory follicular lymphoma (TA604)
Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 604.